Document headings vary by document type but may contain
                    the following: the agency or agencies that issued and signed a document
the number of the CFR title and the number of each part
                      the document amends, proposes to amend, or is directly
                      related to
the agency docket number / agency internal file number
the RIN which identifies each regulatory action listed in
                      the Unified Agenda of Federal Regulatory and Deregulatory
                      Actions See the
                    Document Drafting Handbook
                    for more details.
 Department of Justice Drug Enforcement Administration [Docket No. DEA-392]
 ACTION: Notice of application.
 DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before October 30, 2017.
 ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.


SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.33(a), this is notice that on July 6, 2017, Noramco, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801-4417 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances: Controlled
                             substance
Drug code
ScheduleMarihuana
7360
ITetrahydrocannabinols
7370
ICodeine-N-oxide
9053
IDihydromorphine
9145
IHydromorphinol
9301
I( print page 41056)Morphine-N-oxide
9307
IAmphetamine
1100
IIMethylphenidate
1724
IINabilone
7379
IIPhenylacetone
8501
IICodeine
9050
IIDihydrocodeine
9120
IIOxycodone
9143
IIHydromorphone
9150
IIHydrocodone
9193
IIMorphine
9300
IIOripavine
9330
IIThebaine
9333
IIOpium extracts
9610
IIOpium fluid extract
9620
IIOpium tincture
9630
IIOpium, powdered
9639
IIOpium, granulated
9640
IIOxymorphone
9652
IINoroxymorphone
9668
IITapentadol
9780
II
 The company plans to manufacture the above-listed controlled substances in bulk for distribution to its customers. In reference to drug code 7360, the company plans to manufacture a synthetic version of cannabidiol in bulk for sale to its customers, who are final dosage form manufacturers. No other activity for this drug code is authorized for this registration. Dated: August 21, 2017. Demetra Ashley, Acting Assistant Administrator.


[FR Doc. 2017-18315 Filed 8-28-17; 8:45 am] BILLING CODE 4410-09-P